HSCT Archives - MaaT Pharma

Press Releases

November 3, 2025: MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected for Oral Presentation at ASH Congress 2025

MaaT Pharma Announces Positive Phase 3 Results Evaluating Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease Selected…

MaaT PharmaNovember 3, 2025

Press Releases

July 2, 2024: MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT

MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033…

MaaT PharmaJuly 2, 2024

© 2025 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club